Format

Send to

Choose Destination
Neurol Sci. 2019 Apr 10. doi: 10.1007/s10072-019-03865-9. [Epub ahead of print]

Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine.

Author information

1
Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
2
Biobanca InterIstituzionale Multidisciplinare, IRCCS San Raffaele Pisana, Rome, Italy.
3
Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy.
4
Biotechnology Unit, Istituto Zooprofilattico Sperimentale del Lazio e della Toscana "M. Aleandri", Rome, Italy.
5
Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
6
Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy.
7
Department of Systems Medicine University of Rome "Tor Vergata", Rome, Italy.
8
Evelyn F McKnight Brain Institute, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
9
Biobanca InterIstituzionale Multidisciplinare, IRCCS San Raffaele Pisana, Rome, Italy. raffaelepalmirotta@gmail.com.
10
Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy. raffaelepalmirotta@gmail.com.

Abstract

Dopamine-beta-hydroxylase (DBH) enzyme activity is modulated at the genetic level by the presence of several polymorphisms. Among these, the 19-bp insertion/deletion (I/D) polymorphism (rs72393728/rs141116007) was investigated in several genetic association studies for its correlation with the susceptibility to develop episodic migraine, but conflicting results were achieved. In the present study we analyzed this genetic variant in a carefully characterized population of migraineurs encompassing both episodic and chronic migraine (with and without medication overuse) with the aim to perform a replication study and verify any possible correlation with migraine endophenotypes. Genotyping of the DBH 19-bp I/D polymorphism was performed on 400 migraine patients and 204 healthy individuals. The associations between genotypic frequencies and the clinical and sociodemographic features of migraineurs were then investigated. The DBH 19-bp I/D polymorphism did not correlate with migraine susceptibility or most clinical variables, with the exception of a statistically significant correlation within the subgroup of patients affected by chronic migraine were the individuals carrying the deleted (D) allele were significantly more prone to abuse in analgesics. As a result of this finding, the DBH 19-bp I/D polymorphism does not influence migraine susceptibility, but it might contribute to the development of medication overuse in patient with chronic migraine.

KEYWORDS:

19-bp insertion/deletion polymorphism; Dopamine-beta-hydroxylase; Genetic; Medication overuse; Migraine

PMID:
30972508
DOI:
10.1007/s10072-019-03865-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center